Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423078 · ClinicalTrials.gov registry record · Phase 2
Window of Opportunity in Preserving Laryngeal Function Trial
A Phase 2 study, sponsored by Matthew Spector.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT07423078: Recruiting Phase 2 study, sponsored by Matthew Spector.
NCT07423078 is a Phase 2 study that is actively recruiting participants, run by Matthew Spector. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07423078, a Phase 2 study, is actively recruiting participants, sponsored by Matthew Spector.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
Primary Outcome
Proportion of patients who have not experienced disease recurrence/progression or death from any cause at 1 year from start of treatment. Radiologic (CT or MRI) imaging as well as direct visualization by laryngoscopy will be used to assess disease with recurrence requiring a biopsy to be considered positive.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- RADIATION Radiation Therapy
- DRUG Toripalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2026-04-06 |
| Est. Completion | 2031-04-30 |
| Phase | Phase 2 |
What NCT07423078 shows while recruiting
NCT07423078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT07423078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07423078 about?
NCT07423078 is a clinical study titled "Window of Opportunity in Preserving Laryngeal Function Trial". This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
What is the current status of trial NCT07423078?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2026-04-06. Estimated completion is 2031-04-30.
What interventions are being tested in trial NCT07423078?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION), Toripalimab (DRUG).
Who is sponsoring clinical trial NCT07423078?
This trial is sponsored by Matthew Spector, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07423078's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI